Sanofi SA appoints Norvatis’ executive Paul Hudson to succeed retiring CEO
- Sanofi SA (EPA:SAN) today revealed that Olivier Brandicourt its CEO would retire in September and appointed Paul Hudson as his successor.
- Hudson was an executive at Norvatis where he was CEO of the pharmaceuticals division.
Sanofi issued a statement saying:
“The board of directors would like to thank Olivier Brandicourt for the energy with which he has steered the group through a complex period…”
Serge Weinberg, Sanofi’s board chairman, said:
“We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the group's adaptation to new strategic challenges, particularly in the areas of research and development and digital.”